Overview
Patients diagnosed with cutaneous T-cell lymphoma (CTCL) after using Dupixent (dupilumab) have filed products-liability lawsuits alleging the biologic drug increased their cancer risk (per firm pages, 2026). The cases were centralized in June 2026 as MDL 3180 in the District of New Jersey before Judge Zahid N. Quraishi, with the first lawsuit filed in February 2026 (per LawHum and MDL Radar). Sanofi and Regeneron, the drug’s manufacturers, face the claims; as of September 2026 the MDL is active with no settlement announced (per AboutLawsuits and firm pages).
Status of the science / claims: Plaintiffs allege Dupixent may increase the risk of cutaneous T-cell lymphoma (CTCL); defendants dispute causation (per firm pages and court filings, 2026).
Companies involved
Settlement amounts
No settlement announced as of Sep 2026 (per firm pages). Nothing can be promised.
Case count
| Month | Filed cases | Δ |
|---|---|---|
| Oct 1, 2026 | 45 | — |
Key dates
- September 1, 2026Plaintiffs’ counsel propose leadership positions in the MDL; litigation active, no settlement announced (per AboutLawsuits and firm pages, Sep 2026)
- June 4, 2026JPML centralizes the cases into MDL 3180, D.N.J., before Judge Zahid N. Quraishi (per LawHum and MDL Radar)
- February 13, 2026First Dupixent CTCL lawsuit filed (per LawHum case file)
Updates
- Updated Oct 3, 2026New case (Oct 2026, US): Dupixent (dupilumab) CTCL lawsuits — MDL 3180, D.N.J., Judge Quraishi; centralized Jun 4, 2026 (per LawHum/MDL Radar); active, no settlement (per firm pages, Sep 2026).
Notable filings
No notable filings recorded yet. Docket entries are added from public court records as they appear.
FAQ
Is there a Dupixent cancer lawsuit?
Yes. Patients diagnosed with CTCL after using Dupixent are litigating in MDL 3180, D.N.J., alleging the drug increased their risk (per LawHum and firm pages, 2026).
What is MDL 3180?
The In re Dupixent (Dupilumab) Products Liability Litigation, centralized by the JPML on June 4, 2026, before Judge Zahid N. Quraishi in New Jersey (per LawHum and MDL Radar).
Is there a Dupixent settlement?
No settlement has been announced as of September 2026 (per firm pages).
Can I file a claim?
Plaintiff firms are reviewing Dupixent CTCL claims (per firm pages, 2026). A case review would confirm eligibility; nothing can be promised.
Think this matters to you?
This page is neutral reference material — not legal advice. If you were affected, the next step is a free case review with a licensed attorney working this matter.
Start free case review →